Intersect ENT Inc (XENT) Stock
XENT is no longer traded. Intersect ENT was delisted from the Nasdaq in May 2022.
Prices on this page are historical; the last trade was May 10, 2022 at $28.24.
Intersect ENT stock price history
XENT final trading statistics
- Final close
- $28.24
- Final trading day
- May 10, 2022
- Market cap at delisting
- $954.90M
- Shares outstanding
- 33.81M
- Final 52-week range
- $15.92 – $28.25
- Avg. volume (final 3 mo.)
- 408,884
- All-time high (split-adj.)
- $42.70 · Jun 2018
- All-time low (split-adj.)
- $8.35 · Nov 2016
- Return since IPO
- +118.6%
- Beta
- 1.53
- Book value / share
- $0.48
- Price / book
- 58.23
Intersect ENT annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $106.75M | -$159.6M | -$4.22 |
| FY2020 | $80.55M | -$72.3M | -$2.07 |
| FY2019 | $109.14M | -$43.0M | -$1.37 |
| FY2018 | $108.47M | -$22.9M | -$0.76 |
| FY2017 | $96.30M | -$16.4M | -$0.57 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Intersect ENT Inc
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Intersect ENT stock FAQ
What happened to Intersect ENT stock?
Intersect ENT stock was delisted from the Nasdaq. Its final close was $28.24 on May 10, 2022.
Is XENT stock still trading?
No. XENT was delisted from the Nasdaq in May 2022 and no longer trades on a U.S. exchange.
What was the last price of XENT stock?
XENT closed at $28.24 on its final trading day, May 10, 2022, for a market value of about $954.90M.
What were Intersect ENT's revenue and earnings in its last full fiscal year?
Intersect ENT reported revenue of $106.75M and net income of -$159.6M in fiscal 2021, its last full year as a public company.
When did Intersect ENT go public?
Intersect ENT Inc stock began trading on July 24, 2014.